Exact Sciences Signs Contract with Anthem Blue Cross Blue Shield
News Jun 03, 2016
Exact Sciences Corp. has announced that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin. “As Cologuard’s in-network status grows in 2016, more people gain access to this innovative screening test,” said Kevin Conroy, chairman and CEO of Exact Sciences.
“This access gives us more opportunities to find cancer in its earliest, most treatable stages.” With the recent additions, 69 percent of Anthem’s 37.6 million members now live in states where Cologuard is contracted as an in-network service. Anthem is the second-largest commercial health insurer in the United States.
Exact Sciences has now entered into contracts with Anthem in eight states, including four where Anthem is the largest private insurer in the state (Va., Ga., Ind. and Wis.). Exact Sciences is seeking to enter into similar agreements with additional Anthem affiliates during 2016.
“The momentum continues to build for Cologuard’s commercial coverage and contracting,” said Conroy. “Along with more patients gaining in-network access to our test, the execution of our sales strategy and our consumer marketing efforts continue to drive Cologuard awareness among both patients and physicians.”
Detecting Heart Damage Long Before Parkinson's Symptoms AppearNews
Mapping inflammation in the heart before diagnosis of Parkinson's disease: a new tool for tracking treatment efficacyREAD MORE
Allergic Responses May Protect Against Skin CancerNews
The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings.READ MORE
Potential Treatment for Rare Inherited CancersNews
Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.READ MORE